Bristol-Myers Squibb (BMY) Tops Q1 EPS by 7c, Beats on Revenue
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Bristol-Myers Squibb Co. (BMY) PT Lowered to $53 at Deutsche Bank
April 29, 2024 5:27 AM EDTDeutsche Bank analyst James Shin lowered the price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $53.00 (from $55.00) while maintaining a Hold rating.
The analyst comments "We get it - BMY's cost cut is poor optics given low visibility for late-decade revenues and... More
Bristol-Myers Squibb (BMY) stock slips despite earnings beat
April 25, 2024 7:09 AM EDT(Updated - April 25, 2024 7:26 AM EDT)
Bristol-Myers Squibb (NYSE: BMY) reported better-than-expected earnings and revenue for the first quarter of 2024.
Still, BMY stock fell by 1.7% in premarket trading.
The company reported a loss per share of $4.40, compared to the estimated loss per share of $4.47. Revenue for the quarter reached $11.9 billion, exceeding the consensus... More
